7 registrations that name bifidobacterium longum as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 7 registrations
Status
All 7 registrations
RecruitingNCT07420231
Evaluation of the Synergistic Effect of Combining a Prebiotic and a Postbiotic on Intestinal Discomfort
No phase
Université Catholique de Louvain
About 140 people
Started Mar 16, 2026
In plain words A study of bifidobacterium longum in people 18 to 75, run by Université Catholique de Louvain. It plans to enroll about 140 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Intestinal Discomfort; Abdominal Pain/ Discomfort.
Woman or man, aged of 18 to 75 years (inclusive);
Subject with a measurable level of intestinal discomfort, assessed using a questionnaire inspired by the ROME IV criteria. Eligible participants must meet all of the following conditions:
Experience recurrent abdominal pain present for at least three months and occurring on a regular basis;
The abdominal discomfort must have a low to moderate impact on quality of life;
14 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Berberine; Bifidobacterium longum; Bifidobacterium longum and Berberine; Placebo
Registered summary
This study aims to investigate the beneficial effects of the daily consumption of a synbiotic formulation-combining a prebiotic (Berberine, BBR) and a postbiotic (inactivated Bifidobacterium Longum, B.longum)-in adults experiencing intestinal discomfort.
Where, as registered
No US site; Belgium (1).
RecruitingNCT07691749
Effect of Psychobiotics With Standard Antiddepressants in Treatment of Major Depressive Disorder
No phase
Dr Sadia yasir
About 86 people
Started Jan 31, 2026
In plain words A study of bifidobacterium longum in people 18 to 60, run by Dr Sadia yasir. It plans to enroll about 86 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Major Depression.
Patients diagnosed with major depressive disorder (According to Diagnostic \& Statistical Manual-5 criteria (as per operational definition)
Age 18 to 60 years
Both genders
Patients who are able to speak and understand Urdu/ English language.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Lactobacillus Helveticus and bifidobacterium Longum; Placebo Capsule(s)
Registered summary
The goal of this clinical trial is to learn whether adding psychobiotics (a combination of Lactobacillus helveticus and Bifidobacterium longum) to standard antidepressant treatment works better than antidepressants alone for adults with major depressive disorder. The study will also learn about the safety of taking these psychobiotics with antidepressants. The main questions it aims to answer are: 1. Does adding psychobiotics lower depression symptoms more than a placebo (a look-alike capsule with no active ingredients)? 2. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
RecruitingNCT06729671
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
No phase
University College Cork
About 70 people
Started May 16, 2024
In plain words A study of bifidobacterium longum in people 18 to 65, run by University College Cork. It plans to enroll about 70 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Psychosis.
8.1 Inclusion Criteria To be considered eligible for enrolment into the study, subjects must;
Aged between 18-65 years old including women of child-bearing age
Having a diagnosis of affective or non-affective functional psychosis defined according to ICD-10 criteria for psychosis (codes F20-30 \& F32.3)
Patients who are able to and have given written informed consent
3 more inclusion criteria and the exclusion criteria are on the listing.
Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression. Most antipsychotics are associated with significant weight gain and metabolic disturbances, which increase the risks for other diseases (obesity, diabetes, coronary diseases, etc.) and negatively impact medication adherence and quality of life. Evidence has shown that Olanzapine, for example, increases appetite, food intake, and food reward and modulates the gut microbiota. The full summary is on the listing.
Where, as registered
No US site; Ireland (2).
Not yet recruitingNCT07752342
Exploring Wellbeing Outcomes in Adolescents Using Bifidobacterium Longum, 1714™
No phase
Novonesis
About 150 people
Starts Sep 2026 (estimated)
In plain words A study of bifidobacterium longum in people 15 to 17, run by Novonesis. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 15 to 17; healthy volunteers accepted. Conditions: Healthy Young Adults.
Aged 15-17 years at the time of study screening
Able and willing to provide informed consent or assent, with parental consent where applicable.
Enrolled in school or college at the time of screening
Participants must be able to read and understand English.
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Bifidobacterium longum, 1714™
Registered summary
The purpose of this study is to evaluate changes in self-reported wellbeing outcomes in adolescents. Bifidobacterium longum, 1714™ has previously been associated with beneficial effects on stress-related outcomes, sleep quality, subjective wellbeing and aspects of cognitive performance, however evidence in adolescents is limited. This study will evaluate changes in outcomes related to anxiety, sleep, fatigue, cognitive function and other wellbeing outcomes following daily consumption of Bifidobacterium longum, 1714™ under real-world conditions.
Where, as registered
No US site; United Kingdom (1).
Not yet recruitingNCT07536698
Co-supplementation With Bifidobacterium Longum W11 and Colopectin for Maintenance Therapy in Children With Functional Constipation
No phase
Liaquat University of Medical & Health Sciences
About 100 people
Starts Apr 20, 2026 (estimated)
In plain words A study of bifidobacterium longum in people 2 to 6, run by Liaquat University of Medical & Health Sciences. It plans to enroll about 100 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 2 to 6. Conditions: Functional Constipation.
Children aged 2 to 6 years
Diagnosis of functional constipation
Receiving maintenance therapy with macrogol for at least 3 months
Functional constipation is a common condition in children and often requires prolonged maintenance treatment with macrogol. This randomized, double-blind, placebo-controlled trial will evaluate whether co-supplementation with Bifidobacterium longum W11 and Colopectin can support maintenance therapy in children with functional constipation who are receiving macrogol and are candidates for weaning. Participants aged 2 to 6 years will be randomized to receive either the active supplementation or placebo once daily for 4 weeks, followed by 4 weeks of follow-up after treatment discontinuation. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06639516
Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial
No phase
The First Affiliated Hospital of Nanchang University
About 60 people
Starts Feb 15, 2025 (estimated)
In plain words A study of bifidobacterium longum in people 18 to 75, run by The First Affiliated Hospital of Nanchang University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Acute Pancreatitis.
Age 18-75 year;
The diagnosis of acute pancreatitis according to the revised Atlanta classification;
The onset time of acute pancreatitis is within 48 hours;
APACHE II score of ≥8, or C-reactive protein \> 150 mg/L, or SIRS score of ≥3;
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Bifidobacterium longum; Placebo; Standard clinical treatment
Registered summary
The purpose of this clinical trial is to investigate the impact of Bifidobacterium longum(BL) on the clinical prognosis of patients with acute pancreatitis(AP), to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL. Participants will be randomly assigned to two groups: the intervention group and the control group. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07705659
A Probiotic for Health Outcomes in Short-Term Overseas Travel
No phase
DiproBio (Shanghai) Co., Ltd.
About 40 people
Starts Jul 30, 2026 (estimated)
In plain words A study of bifidobacterium longum in people 18 to 65, run by DiproBio (Shanghai) Co., Ltd.. It plans to enroll about 40 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Changes in Gut Microbiota, Gut Metabolites, Respiratory Symptoms, and Well-being Index.
Age: 18-65 years, inclusive, with no restriction on gender.
Planned short-term round-trip travel from China to an overseas destination, with a total travel duration of no more than 7 days.
Volunteers must be able to understand and comply with the study protocol, and provide written informed consent prior to initiation of any study procedures.
The exclusion criteria are on the listing.
What it tests, as registered
Bifidobacterium longum; Maltodextrin
Registered summary
With the improvement of living standards, travel has become a common form of leisure. However, travelers often face changes in living environments, dietary habits, and sleep schedules, all of which can impact the gut microbiota and lead to a range of health issues. Dietary changes during travel are one of the key factors affecting gut microbiota. Food composition and preparation methods vary widely across regions, introducing novel bacterial strains into the gut. The full summary is on the listing.
Where, as registered
No sites listed yet.
ClinicalTrials.gov lists 33 open registrations for this search, including ones where bifidobacterium longum is not a study arm or that are past the 7 we keep. Search them on ClinicalTrials.gov (opens in new tab).